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Propionate protects haloperidol-induced neurite lesions mediated by
neuropeptide Y
Abstract
Haloperidol is a commonly used antipsychotic drug for treating schizophrenia. Clinical imaging studies
have found that haloperidol can cause volume loss of human brain tissue, which is supported by animal
studies showing that haloperidol reduces the number of synaptic spines. The mechanism remains
unknown. Gut microbiota metabolites, short chain fatty acids including propionate, are reported to have
neuroprotective effect and influence gene expression. This study aims to investigate the effect and
mechanism of propionate in the protection of neurite lesion induced by haloperidol. This study showed
that 10 μM haloperidol (clinical relevant dose) impaired neurite length in human blastoma SH-SY5Y cells,
which were confirmed by using primary mouse striatal spiny neurons. We found that haloperidol impaired
neurite length were accompanied by a decreased neuropeptide Y (NPY) expression, but no effect on
GSK3β signaling. Importantly, this project research found that propionate was capable of protecting
against haloperidol-induced neurite lesions and preventing NPY reduction. To confirm this finding, we
used specific siRNAs targeting NPY which blocked the protective effect of propionate on haloperidolinduced neurite lesions. Furthermore, since NPY is regulated by the nuclear transcription factor CREB, we
measured pCREB that was decreased by haloperidol and was normalized by propionate. Therefore,
propionate has a protective effect against pCREB-NPY mediated haloperidol-induced neurite lesions.
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Haloperidol is a commonly used antipsychotic drug for treating schizophrenia. Clinical
imaging studies have found that haloperidol can cause volume loss of human
brain tissue, which is supported by animal studies showing that haloperidol reduces
the number of synaptic spines. The mechanism remains unknown. Gut microbiota
metabolites, short chain fatty acids including propionate, are reported to have
neuroprotective effect and influence gene expression. This study aims to investigate
the effect and mechanism of propionate in the protection of neurite lesion induced
by haloperidol. This study showed that 10 µM haloperidol (clinical relevant dose)
impaired neurite length in human blastoma SH-SY5Y cells, which were confirmed by
using primary mouse striatal spiny neurons. We found that haloperidol impaired neurite
length were accompanied by a decreased neuropeptide Y (NPY) expression, but no
effect on GSK3β signaling. Importantly, this project research found that propionate was
capable of protecting against haloperidol-induced neurite lesions and preventing NPY
reduction. To confirm this finding, we used specific siRNAs targeting NPY which blocked
the protective effect of propionate on haloperidol-induced neurite lesions. Furthermore,
since NPY is regulated by the nuclear transcription factor CREB, we measured pCREB
that was decreased by haloperidol and was normalized by propionate. Therefore,
propionate has a protective effect against pCREB-NPY mediated haloperidol-induced
neurite lesions.
Keywords: antipsychotic drug, haloperidol, neurite impairment, propionate, neuropeptide Y

INTRODUCTION
Antipsychotic drugs are the primary therapeutic agents used to treat schizophrenia and its
allied mental disorders (Huang and Song, 2018). Among them, haloperidol is the firstgeneration antipsychotic drug and widely used to treat schizophrenia patients (Tardy et al., 2014).
Haloperidol acts on the dopamine D2 receptors (D2R) and controls psychotic symptoms including
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hallucinations, delusions, and aggressiveness (Jafari et al., 2012;
Dold et al., 2015). However, it can also cause various side
effects including extrapyramidal syndrome, tardive dyskinesia,
and cerebrovascular events (Hufner et al., 2015). In brain
morphology, chronic application of haloperidol has been
reported to reduce brain volume (Ho et al., 2011). A number of
studies have suggested that chronic or accumulative haloperidol
administration can decrease synaptic spines and induce apoptosis
(Frost et al., 2010; Nandra and Agius, 2012). A chronic
application of haloperidol induces neurite lesion reported in
human, animal, and cell-based studies (Kelley et al., 1997; DorphPetersen et al., 2005; Critchlow et al., 2006; Ho et al., 2011).
A meta-analysis revealed that higher daily haloperidol intake
in patients resulted in greater cortical gray matter reduction
(Z, −2.31, p = 0.02) (Vita et al., 2015). Animal study shows that
macaque monkeys treated with haloperidol for 17 to 27 months
have a reduced brain weight by 8–11%, and these reductions
were consistent across a number of brain areas (Dorph-Petersen
et al., 2005). Another study shows that chronic administration
of haloperidol at ∼0.35 mg/kg at 2-week intervals for 1 year
significantly reduces neuronal cytoskeleton and spine-associated
proteins in the cortices of rhesus monkey, where are rich in
dopamine innervation and are implicated in the psychopathology
of schizophrenia (Lidow et al., 2001). Therefore, there is an urgent
need to search for a way to protect antipsychotic drug-induced
neurite lesion.
Our previous study shows that haloperidol decreases
neuropeptide Y (NPY) mRNA expression in the rat brain after
haloperidol treatment (Huang et al., 2006). NPY is highly
co-expressed in GABAergic neurons and is found to be a
modulator of the neuroplasticity, neurotransmission, and
memory (Gotzsche and Woldbye, 2016). Given these evidence,
we have investigated whether or not NPY was involved in
haloperidol-induced neurite lesion.
Short chain fatty acid (SCFA) including acetate, propionate,
and butyrate are the metabolites produced by gut microbiome
fermentation on dietary fiber. SCFA can enter the circulation via
monocarboxylate transporters, cross the blood–brain barrier, and
thereby enter the central nervous system (Pierre and Pellerin,
2005; Kekuda et al., 2013). More and more evidence show
that SCFA regulate cell metabolism (Canfora et al., 2015),
neurotransmitter synthesis and release (DeCastro et al., 2005;
Shah et al., 2006), epigenetics (Yamawaki et al., 2012), and
immune function (Correa-Oliveira et al., 2016). In particular,
propionate and butyrate act as the histone deacetylases inhibitors
(HDACi). HDACi regulates brain gene expression, improving
the healthy state of patients suffering from Parkinson’s disease,
depression, and schizophrenia (Galland, 2014). However, the
neurite protective, at high concentrations, propionate has also
been reported to induce autism-like behavioral changes in
rats (Macfabe, 2012). Collectively, these reports suggest that
propionate may play an important role in neural function. Our
study investigated whether or not propionate may be used to
prevent haloperidol-induced neurite lesions. Furthermore, we
have investigated the CREB-NPY signaling pathway in mediating
the neurite protective effect of propionate in haloperidol-induced
neurite lesion.
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MATERIALS AND METHODS
Cell Culture and Treatments
The undifferentiated human SH-SY5Y neuroblastoma cell line
were grown in Dulbecco’s modified Eagle’s medium (DMEM)F12 supplemented with 1% penicillin–streptomycin and 10%
heat-inactivated fetal bovine serum (FBS) from Bovogen
Biologicals (Victoria, Australia). For differentiation, cells were
seeded in culture plates coated with MaxGelTM ECM (E0282,
Sigma Aldrich, Syndey). In the following day, media was
removed and replaced with 10 µM retinoic acid (RA, R2625;
Sigma-Aldrich) in DMEM-F12 with 1% FBS. Haloperidol (MP
Biomedicals, Solon, OH) was dissolved in 100% dimethyl
sulfoxide (Sigma-Aldrich). Sodium propionate was purchased
from Sigma-Aldrich. Cells were treated with media containing
either haloperidol or haloperidol with different concentrations of
propionate. The neurite length was acquired in real time every
6 h for 24 h using IncucyteZoom Machine and analyzed with the
Neuro Track software (Sartorius, Michigan).

Gene Transfection
The siNPYs (siNPY_001: 50 CAGACCTCTTGATGAGAGA30 ;
siNPY_002: 50 CGCTGCGACACTACATCAA30 ; siNPY_003:
50 GAGGACATGGCCAGATACT30 ) and respective negative
control (NC) were synthesized (RiboBio, Guangzhou) and
dissolved in the DEPC H2 O. Transfections of siRNAs were
performed with the Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) following the manufacturer’s instructions. Medium was
changed to the differentiation medium containing various
treatments 6 h later.

Primary Striatal Neuronal Culture
Cultured striatal neurons were harvested from postnatal days
0 to 3 of C57Bl mice. Briefly, striatal neurons were gently
dissociated with a plastic pipette after digestion with 0.5% trypsin
(GIBCO, Los Angeles) at 37◦ C for 30 min. Neurons were cultured
in neurobasal medium (GIBCO) containing B27 supplement
(GIBCO) and 20 mM glutamine (Sigma Aldrich). After 24 h of
culture, 5-fluoro-20 -deoxyuridine (Sigma Aldrich) was added at
a final concentration of 10 µM to repress the growth of glial
cells. Cultures were maintained at 37◦ C in a humidified 5% CO2
incubator for 7 days (DIV7) prior to treatments. All experimental
procedures for primary cell culture were approved by the Animal
Ethics Committee, University of Wollongong, Australia, and
complied with the Australian Code of Practice for the Care and
Use of Animals for Scientific Purposes.

Western Blot
After 24 h treatments, cells were harvested with lysis
buffer containing NP40 (Sigma-Aldrich), Protease Inhibitor
Cocktail (Sigma-Aldrich), 1 mM PMSF (Sigma-Aldrich), and
0.5 mM β-glycerophosphate (Sigma-Aldrich). Total protein
concentrations were determined by DC-Assay (Bio-Rad,
Sydney) and detected with a SpectraMax Plus384 absorbance
microplate reader (Molecular Devices, Sunnyvale, CA). Samples
were heat-treated in Laemmli buffer at 95◦ C, loaded to
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FIGURE 1 | Haloperidol inhibited neurite outgrowth. (A) Neurite length was reduced in a dose dependent manner by 1, 10, and 50 µM haloperidol treatments in
SH-SY5Y cells for 24 h (n = 3–4); (B) representative images of cells with (10 µM) and without (0 µM) haloperidol treatments in SH-SY5Y cells; (C) haloperidol
(10 µM) decreased neurite length/cell in primary striatal neurons (n = 6); (D) primary striatal neurons stained with MAP2 antibody and imaged with
immunofluorescence confocal microscope. Mean ± SEM, ∗∗∗ p < 0.001.

secondary antibody Alexa Fluor 488-conjugated donkey antimouse IgG (Invitrogen, Carlsbad, CA) or Alexa Fluor 488conjugated donkey anti-rabbit IgG (Invitrogen, Sydney), Alexa
FluorTM 647-conjugated donkey anti-mouse IgG (Invitrogen),
and Alexa Fluor 568 Phalloidin (A12380, Invitrogen) at room
temperature for 2 h.
For SH-SY5Y cells, cells were seeded in the ibidi glass
bottom dish (ibidi GmbH, Germany), treated with either
haloperidol, haloperidol + propionate, propionate, or nil control
in differentiated medium for 24 h, and then the above steps
were followed by immunofluorescence assays. We applied the
primary antibodies including pCREB (sc-101662, Santa Cruz
Biotechnology) and MAP2 to cells at 4◦ C overnight, followed
by incubation in a secondary antibody cocktail of Alexa Fluor
488-conjugated donkey anti-rabbit IgG (Invitrogen) and Alexa
Fluor 647-conjugated donkey anti-mouse IgG (Invitrogen) at
room temperature for 2 h. Cells were viewed using 40×
or 63× oil immersion objective on a DMI6500B confocal
microscope (Leica, Mannheim, Germany). The neurite length
and protein expression were measured using the ImageJ
Software.

10% SDS-PAGE gels (Bio-Rad) for fractionation, and then
transferred into Immun-Blot TM PVDF membranes (BioRad). The blocking buffer consisted of 5% slim milk in TBST.
The membranes were incubated with NPY (sc-28943, Santa
Cruz Biotechnology, Santa Cruz), phospho-GSK3β(Ser9)
(#9323s, Cell Signaling Technology), and β-Catenin (#8480s,
Cell Signaling Technology) antibodies in TBST containing
1% milk at 4◦ C overnight. Secondary antibodies were
anti-rabbit IgG conjugated with horseradish peroxidase
(Santa Cruz Biotechnology). For visualization, we used
ECL detection reagents and obtained high resolution
images with Amersham Gel Imager (GE Healthcare life
Sciences).

Immunofluorescence Assay
Primary striatal neurons were grown to approximately 70%
confluence on glass coverslips and treated with either negative
control, haloperidol, haloperidol + propionate, or propionate for
24 h before being fixed in 4% formaldehyde for 15 min. Neurons
were washed in PBS, and permeabilized with 0.3% Triton X100 in PBS for 10 min. After blocking with 5% normal donkey
serum for 1 h at room temperature, primary antibodies of MAP2
(M4403-2ML, Sigma-Aldrich), NPY, or GAD67 (MAB5406,
Millipore, Bedford) were applied in 1% donkey serum in
PBS at 4◦ C overnight. This was followed by incubation in a
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Spine Morphology
Primary striatal neurons were cultured for 14 days (DIV14)
and were used for spine morphology study. The procedure
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FIGURE 2 | Haloperidol reduced neuropeptide Y (NPY); however, haloperidol did not change GSK3β signaling. (A–C) Haloperidol (10 µM) reduced the neurite
length, but no changes were found in pGSK3βSer9 and β-catenin signaling in SH-SY5Y cells measured by Western blot (n = 3); (D,E) haloperidol (10 µM) reduced
NPY expression in SH-SY5Y cells (n = 3). Mean ± SEM, ∗∗ p < 0.01.

outgrowth in a dose-response manner [F(3,11) = 145.401,
p < 0.001, Figure 1A]. The neurite length was significantly
shorter compared with control group after 1, 10, and 50 µM
haloperidol treatments (all p < 0.001). As it is known that the
plasma concentration of haloperidol-treated patients is between
2 and 10 ng/ml (Volavka et al., 1995), we used 3.8 ng/ml or
10 µM concentration of haloperidol. We repeated the results with
10 µM haloperidol and confirmed its effect on neurite inhibition
(Figure 1B). To confirm these observations, we applied the same
concentration of haloperidol in primary striatal neurons. We
found that haloperidol treatment at 10 µM for 24 h significantly
reduced neurite length visualized by MAP2 staining (p < 0.001,
Figures 1C,D).

was similar to the Immunofluorescence assay. After blocking,
neurons were incubated with Alexa FluorTM 568 Phalloidin
(A12380, Invitrogen) for 1 h and washed with PBS. Neurons
were viewed using a 63× oil immersion objective on a DMI6500B
confocal microscope (Leica, Mannheim, Germany). The number
of synaptic spines was measured using ImageJ Software.

Statistics
SPSS program (version 21; Chicago, IL, United States) was used
for statistical analysis. One-way analysis of variance (ANOVA)
followed by post hoc Tukey’s tests was performed for multiple
comparisons. Data were expressed as mean ± SEM, and p < 0.05
value was considered statistically significant.

Haloperidol Inhibited Neurite Outgrowth

Haloperidol-Induced Neurite Lesions Did
Not Alter GSK3β Signaling but
Decreased NPY Expression

In order to investigate the effects of haloperidol on neurite
morphology, RA-induced differentiated SH-SY5Y cells were
incubated with various concentrations of haloperidol (0, 1, 10,
50 µM) for 24 h. The neurite length was measured in realtime. Haloperidol treatment significantly reduced the neurite

We examined GSK3β signaling since this signaling pathway is
involved in neurogenesis and synaptic plasticity (Cole, 2013).
No changes were detected in pGSK3β and β-catenin expression
after 10 µM haloperidol treatment (p > 0.05, Figures 2A–C).
However, we found a significant reduction of NPY expression

RESULTS

Frontiers in Neuroscience | www.frontiersin.org
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FIGURE 3 | Propionate protected neurite lesions. (A) Neurite lesions induced by 10 µM haloperidol were protected by 100 µM propionate in SH-SY5Y cells
(n = 3–4); (B) Propionate prevented the haloperidol-induced neurite lesion in primary striatal neurons (n = 6); (C) Propionate prevented the haloperidol-induced
synaptic spine reduction in primary striatal neurons (n = 6); (D) The striatal neurons were stained with MAP2 antibody (Top row). Synaptic spines were stained with
Alexa FluorTM 568 Phalloidin (Bottom row) and imaged with immunofluorescence confocal microscope. Cells were treated for 24 h. Mean ± SEM, ∗ p < 0.05,
∗∗ p < 0.01, ∗∗∗ p < 0.001.

propionate (Figure 3B, p < 0.01). It has been reported that
haloperidol can decrease the number of synaptic spines in the
rat striatum (Kelley et al., 1997). We quantified the number of
basilar synaptic spines. We found that propionate prevented the
loss of synaptic spines-induced by haloperidol [F(3,20) = 9.994,
p < 0.001, Figures 3C,D].

after 10 µM haloperidol treatment in SH-SY5Y cells (p < 0.01,
Figures 2D,E). The results suggested that NPY was associated
with neurite reduction induced by haloperidol.

Propionate Prevented Neurite
Lesion-Induced by Haloperidol
Previous studies suggest that propionate may play important
roles in neurodevelopment. We tested whether or not propionate
could prevent haloperidol-induced neurite deficit. We treated
SH-SY5Y cells with sodium propionate at concentrations of 0,
10, 50, and 100 µM (Fasting plasma concentration in humans is
about 24 µM.) for 30 min prior to 10 µM haloperidol treatment.
We observed that propionate prevented neurite impairment
induced by haloperidol [F(4,11) = 5.357, p = 0.012, Figure 3A].
Specifically, 100 µM propionate completely prevented neurite
lesions induced by haloperidol (p < 0.05). Furthermore, we
investigated if propionate could prevent neurite lesion in
primary mouse striatal neurons. Our results showed that
propionate prevented neurite lesion induced by haloperidol
[F(3,20) = 11.656, p < 0.001, Figures 3B,D]. Post hoc analysis
showed that the neurite lesions was prevented by 100 µM

Frontiers in Neuroscience | www.frontiersin.org

Propionate Prevented NPY Reduction
Induced by Haloperidol
Since we observed that the neurons with neurite deficits
induced by haloperidol have decreased NPY, we examined
if propionate could prevent the reduced NPY. We found
that propionate completely prevented NPY reduction
induced by haloperidol in SH-SY5Y cells [F(3,8) = 17.502,
p = 0.001, Figure 4A]. This result supported our above
discovery that NPY is involved in haloperidol-induced
neurite lesions and propionate prevented neurite lesions
were involved in the regulation of NPY. Furthermore,
we used primary mouse striatal neurons to validate our
finding. Again, we found that haloperidol significantly
reduced NPY, which could be prevented by propionate in
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FIGURE 4 | Propionate prevented the NPY reduction induced by haloperidol. (A) Propionate (100 µM) protected haloperidol induced NPY reduction in SH-SY5Y
cells (n = 3); (B) propionate prevented NPY reduction induced by haloperidol in primary striatal neurons (n = 6); (C) these striatal NPY neurons were GAD67 positive
indicating that NPY and GABA are co-localized in these neurons. The morphological appearance showed these are medium sized spiny neurons with body size of
∼10 µM in diameter. Mean ± SEM, ∗∗ p < 0.01.

CREB Phosphorylation Was Involved in
the Neuronal Protective Effect of
Propionate

the striatal neurons [F(2,15) = 12.346, p = 0.001, Figures 4B,C].
Further characterization was performed using glutamic acid
decarboxylase 67 (GAD67) antibody staining for GABA synthesis
(Chattopadhyaya et al., 2007). We showed these haloperidolresponding striatal neurons contained both NPY and GABA
(Figure 4C).
Furthermore, to confirm the role of NPY in propionateinduced neuroprotection against haloperidol-induced neurite
lesions, we used specific siRNA to knock down NPY in
SH-SY5Y cells (Figures 5A–C). In this case, propionate
was no longer able to protect the neurite lesion-induced
by haloperidol [F(3,8) = 11.788, p = 0.003, Figure 5A].
As shown that the neurite lesions induced by haloperidol
(p < 0.01) was protected by 100 µM propionate (p < 0.05),
while siNPY abolished the neural protective effects of
propionate. Western blotting results showed that the NPY
was reduced in NPY-siRNA treated cells compared with the
cells without NPY-siRNA treatment (p < 0.05, Figures 5B,C).
Similarly, propionate prevented neurite lesion in primary
mouse striatal neurons but not after NPY-siRNA treatment
[F(3,20) = 29.663, p < 0.001, Figures 5D,E]. These results
indicated that propionate protective effect was mediated
by NPY.

Frontiers in Neuroscience | www.frontiersin.org

The cAMP responsive element binding protein (CREB) is
a ubiquitous transcription factor located in CRE promoter
regions, which modulates the transcription of genes with cAMP
responsive elements (CRE). Since it is known that CREB gene
transcription factor regulates NPY expression in neurons, we
investigated possible correlations between phosphorylated CREB
in our propionate treated cells. As expected, we observed
that haloperidol decreased CREB phosphorylation, which was
prevented by propionate; however, propionate alone did not
alter CREB phosphorylation [F(3,20) = 14.741, p < 0.001,
Figures 6A,B]. These data suggested that propionate could
prevent the down-regulation of CREB phosphorylation induced
by haloperidol, which in turn prevented down-regulation of NPY
and neurite lesions (Figure 7).

DISCUSSION
Antipsychotic drugs are widely used in treating schizophrenia
and allied disorders. However, antipsychotic drug treatment
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FIGURE 5 | The treatment of NPY-siRNA (siNPY) eliminated the protective effects of propionate on the neurite impairment-induced by haloperidol. (A) The
quantification of neurite length of SH-SY5Y cells treated with/without siNPY (n = 3); (B,C) the treatment of siNPY eliminated the effect of propionate in preventing
haloperidol induced NPY reduction in SH-SY5Y cells (n = 3); (D) fluorescence confocal images of striatal neurons stained for MAP2, and (E) quantification of neurite
length showed that the treatment of siNPY eliminated the effect of propionate in preventing haloperidol-induced neurite lesions in primary striatal neurons (n = 6).
Mean ± SEM, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

FIGURE 6 | Propionate protected the reduction of CREB phosphorylation (pCREB) induced by haloperidol in SH-SY5Y cells. (A) Fluorescence confocal images of
SH-SY5Y cells showed that haloperidol reduced pCREB which was prevented by propionate (Top row), cell contour showed by MAP2 staining (middle row), and
merge (bottom row). (B) The quantification of pCREB immunofluorescence intensity (n = 6). Mean ± SEM, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

could result in neurite lesion in brain areas, rich in dopamine
D2R (Huang and Song, 2018). This is because D2R plays
an important role in neurite growth and synaptogenesis

Frontiers in Neuroscience | www.frontiersin.org

(Jia et al., 2013) and virtually all antipsychotic drugs have D2R
antagonist properties (Jafari et al., 2012; Huang and Song, 2018).
Haloperidol is a typical antipsychotic drug having strong D2R
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study, which we have demonstrated that haloperidol decreases
NPY expression in the rat amygdala and hippocampus (Huang
et al., 2006). Other studies have shown that haloperidol decreases
NPY in the striatum, but increases in the hypothalamus (Gruber
and Mathe, 2000). The present study showed that propionate
prevented haloperidol-induced NPY reduction in SH-SY5Y and
striatal neurons. When we used NPY-siRNA to decrease NPY
activity, we found that the protective effect of propionate
against haloperidol-induced lesion in neurites was eliminated.
Collectively, these results support the idea that the NPY pathway
was involved in the prevention of haloperidol-induced neurite
lesion by propionate.
The mechanism underlying haloperidol decreasing NPY
expression is not clear. One possibility could be via CREB
signaling. CREB is a transcriptional coactivator involved in
the regulation of synaptic plasticity and long-term memory
through activation of gene transcription (Vecsey et al., 2007).
It is known that the CREB pathway regulates NPY expression
(Wand, 2005). It has also been demonstrated that D2R
regulates CREB. For example, D2R agonist quinpirole stimulates
CREB phosphorylation by activating protein kinase C and
Ca2+ /calmodulin-dependent protein kinase (Yan et al., 1999).
In addition, GSK3β signaling pathway is involved in
neurogenesis and synaptic plasticity (Cole, 2013). Previous
studies have reported that haloperidol does not change the
GSK3β pathway in SH-SY5Y cells and in primary hippocampal
neurons (Park et al., 2009, 2011). In agreement with their studies,
we did not find a change of GSK3β signaling after haloperidol
treatment. Our study showed that haloperidol reduced CERB
phosphorylation, which was prevented by propionate. Therefore,
it is suggested that haloperidol may act on other D2R protein
kinase dependent pathway to inhibit pCREB rather than
the pGSK3β signaling pathway as per previous observations
(Borroto-Escuela et al., 2013; Fuxe et al., 2014).
It is known that short chain fatty acids are ligands for
G-protein coupled receptors GPR41 and GPR43 (Tan et al.,
2014), which have no other known ligands (Tazoe et al., 2008).
Until now, no GPR41 or GPR43 receptors have been reported
in the brain. On the other hand, it is known that short
chain fatty acids can directly enter brain and interact with
neurons (Erny et al., 2015; Stilling et al., 2016). Our study
showed that propionate prevented haloperidol-induced neurite
lesions in a dose-dependent manner. The concentration of
propionate is between 14 to 19 mM in human feces (Schwiertz
et al., 2010) and 19.4 to 28.5 µM in human fasting plasma,
which could vary depending on the detection method used
or a person’s dietary profile (De Filippo et al., 2010). It is
possible that increasing propionate by either delivering highly
concentrated propionate capsule or providing selected dietary
fiber may provide a possible protective effect against neurite
lesion.

FIGURE 7 | Proposed mechanism of propionate preventing
haloperidol-induced neurite lesion in vitro. Haloperidol inhibited pCREB-NPY
signaling causing neurite deficit. Propionate prevented haloperidol-induced
reduction of pCREB-NPY signaling, which reversed neurite deficits.

antagonist property. Plasma concentrations of patients treated
with haloperidol are between 2 to 10 ng/ml (Volavka et al., 1995).
This study used a clinical relevant dose 3.8 ng/ml (equivalent to
10 µM; molecular weight of haloperidol is 376 g/mol), which
resulted in neurite lesions in both SH-SY5Y and primary striatal
neurons. A previous study has shown that 0.1 µM haloperidol
treatment decreases the dendritic spine density as well as spinesenriched proteins of rat hippocampal neurons (Critchlow et al.,
2006). Similarly, chronic haloperidol treatment (1.5 mg/kg daily
similar to human dose) results in 58% reduction of spine density
in rat striatum (Kelley et al., 1997). These data provide strong
evidence that clinically used doses of haloperidol may cause
neurite lesion.
Propionate is a short chain fatty acid which is a product
of gut microbiome fermentation of dietary fiber (Neis et al.,
2018). Short chain fatty acids can affect brain function and
behavior (Selkrig et al., 2014). Our study showed that propionate
prevented neurite lesions-induced by haloperidol. Previous study
has suggested that propionate can have significant effects on brain
neurites. For example, children with autistic spectrum disorders
are characterized by elevated concentrations of propionate, which
may link to exaggerated neural synaptic spine formation (Penzes
et al., 2011; Frye et al., 2015). Introducing propionate into brain
ventricle could induce autism-like behavioral changes in rats
(MacFabe et al., 2007, 2011). Our study showed that propionate
protected the neurite and synaptic spine lesion induced by
haloperidol supporting the effect of propionate on promoting
neurite outgrowth.
NPY is highly expressed in striatal GABAergic neurons and
regulates GABA and glutamate release potentially contributing to
neuroprotection, learning, and memory (Gotzsche and Woldbye,
2016). The present study showed that haloperidol decreased
NPY expression in both human blastoma SH-SY5Y and primary
striatal neurons. This is in consistent with our early in vivo

Frontiers in Neuroscience | www.frontiersin.org

CONCLUSION
Our study showed that haloperidol reduced neural pCREBNPY signaling, which was involved in neurite and synaptic
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spine lesions. Propionate prevented haloperidol-induced neurite
lesions via increased pCREB-NPY signaling in vitro. Further
study needs to be performed to examine if propionate could
protect neurite lesion induced by haloperidol in vivo.
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